Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 December 2021 | Story Lunga Luthuli | Photo Supplied
Geraldine Lengau, Senior Officer in the UFS Gender Equality and Anti-Discrimination Office within the Unit for Institutional Change and Social Justice, calls on men to take the lead in ending gender-based violence.

Gender-based violence is a phenomenon deeply rooted in gender inequality and the scourge continues to be one of the most notable human rights violations, with many communities – especially women and children – suffering the most from the atrocious acts. 

South Africa remains the country with the highest number of violent acts, especially against women, and Statistics South Africa reports that one in five partnered women has experienced physical violence. 

Gender-based violence can take many forms, including 

• sexual harassment; 
• rape and/or sexual violence;
• stalking (deliberately and repeatedly following, watching, and/or harassing another person);
• physical, emotional, and economic abuse; and
• child abuse.

Geraldine Lengau, Senior Officer in the Gender Equality and Anti-Discrimination Office within the Unit for Institutional Change and Social Justice, says: “Individuals must be vigilant of toxic environments where emotional and physical abuse are rampant.”

 “Even in the workplace, individuals can experience gender-based violence and it can play itself out in the form of power dynamics, prejudice, and discrimination.”

To help end gender-based violence at work, Lengau says, “Institutions have a duty to implement policies and procedures to increase awareness and sensitisation about this pandemic.”

Societal norms often contribute to victims deciding not to report these criminal acts for fear of being judged, with many women still being considered guilty of attracting violence against themselves through their behaviour.

“It is important for communities to provide support to victims and for organisations to have a zero gender-based violence tolerance policy. Victims must report any act, and in extreme cases, they must not be shy to get a protection order,” Lengau says. 

With the 16 Days of Activism for No Violence against Women and Children Campaign in full swing, Lengau says, “It is a great international initiative to tackle and raise awareness around issues of gender-based violence; however, it is not enough. It should go beyond the 16 days.”

 “To rid society of gender-based violence, our communities – men and women – should work together to root it out. Men should take the lead in tackling issues and bringing about solutions. Women should never get tired of speaking out; there is help for them.”

“Gender-based violence is a societal ill and women need to know that they should not bear the shame,” she says.

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept